Against a backdrop where the life-or-death consequences of biotechnology innovation are becoming increasingly apparent as the world races to develop vaccines and therapies to treat COVID-19, life sciences investor ARCH Venture Partners has raised $1.46 billion in funding to finance new tech development. The two funds, ARCH Venture Fund X and ARCH Venture Fund X … Continue reading ARCH Venture Partners raises $1.46 billion across two funds for biotech investing